Neovacs, a leader in active immunotherapies for the treatment of autoimmune diseases, has established a U.S. subsidiary, Neovacs, Inc., headquartered in Boston. The creation of this U.S. subsidiary marks an important strategic step for Neovacs, as the company extends its clinical initiatives for lead product candidate, IFNalpha-Kinoid, beyond the EU to the U.S. market. The establishment of this subsidiary follows the formation of a U.S. Scientific Advisory Board in October 2013. Arlene Morris...